Acumen Pharmaceuticals, Inc. (ABOS) Latest Company News

Oct 26, 2026, 11:00 UTC
Acumen Pharmaceuticals, Inc. said it is targeting a mid-2027 IND filing for the lead clinical candidate in its Enhanced Brain Delivery program.
Source:
- globenewswire.com
Oct 26, 2026, 11:00 UTC
Acumen Pharmaceuticals, Inc. said it expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) in November 2026.
Source:
- globenewswire.com
Oct 26, 2026, 11:00 UTC
Acumen Pharmaceuticals, Inc. reported third-quarter 2026 financial results, including $78.6 million in cash, cash equivalents and marketable securities as of September 30, 2026.
Source:
- globenewswire.com
Oct 22, 2026, 11:30 UTC
Acumen Pharmaceuticals, Inc. announced that it will present three posters on its Phase 2 ALTITUDE-AD trial at the CTAD conference in Boston.
Source:
- globenewswire.com
Oct 19, 2026, 20:00 UTC
Acumen Pharmaceuticals, Inc. announced that it will report third-quarter 2026 financial results and host a business and financial update call and webcast on October 26, 2026, at 8:00 a.m. ET.
Source:
- globenewswire.com
Sep 10, 2026, 20:00 UTC
Acumen Pharmaceuticals announced it will host a virtual Investor Day on September 16, 2026.
Source:
- globenewswire.com
Aug 12, 2026, 14:57 UTC
Acumen Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.
Source:
- seekingalpha.com
Aug 12, 2026, 00:00 UTC
Acumen Pharmaceuticals reported a net loss of $32.7 million for Q2 2026, with research and development expenses of $27.8 million and cash and marketable securities of $110.2 million as of June 30, 2026.
Jun 17, 2026, 16:30 UTC
Acumen Pharmaceuticals exercised its exclusive option to develop therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' J-Brain Cargo technology platform.
Jun 16, 2026, 11:30 UTC
Acumen Pharmaceuticals nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program for Alzheimer's disease treatment.
Source:
- globenewswire.com

ABOS

Acumen Pharmaceuticals, Inc. said it is targeting a mid-2027 IND filing for the lead clinical candidate in its Enhanced Brain Delivery program.

Acumen Pharmaceuticals, Inc. said it expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) in November 2026.

Acumen Pharmaceuticals, Inc. reported third-quarter 2026 financial results, including $78.6 million in cash, cash equivalents and marketable securities as of September 30, 2026.

Acumen Pharmaceuticals, Inc. announced that it will present three posters on its Phase 2 ALTITUDE-AD trial at the CTAD conference in Boston.

Acumen Pharmaceuticals, Inc. announced that it will report third-quarter 2026 financial results and host a business and financial update call and webcast on October 26, 2026, at 8:00 a.m. ET.

Acumen Pharmaceuticals announced it will host a virtual Investor Day on September 16, 2026.

Acumen Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.

Acumen Pharmaceuticals reported a net loss of $32.7 million for Q2 2026, with research and development expenses of $27.8 million and cash and marketable securities of $110.2 million as of June 30, 2026.

Acumen Pharmaceuticals exercised its exclusive option to develop therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' J-Brain Cargo technology platform.

Acumen Pharmaceuticals nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program for Alzheimer's disease treatment.